Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Epidemiol Biomarkers Prev ; 31(12): 2185-2191, 2022 12 05.
Article in English | MEDLINE | ID: mdl-36126275

ABSTRACT

BACKGROUND: High-risk human papillomavirus (HR-HPV) infection is a risk factor for anal cancer, yet no anal cancer screening guidelines exist for women with lower genital tract HPV-related disease. We sought to describe the prevalence of anal HR-HPV or cytologic abnormalities in such women. METHODS: This cross-sectional study was performed between October 2018 and December 2021. Inclusion criteria were ≥21 years of age and a prior diagnosis of high-grade dysplasia/cancer of the cervix, vagina, or vulva. Participants underwent anal cytology and anal/cervicovaginal HR-HPV testing. Women with abnormal anal cytology were referred for high-resolution anoscopy (HRA). RESULTS: 324 evaluable women were enrolled. Primary diagnosis was high-grade dysplasia/cancer of the cervix (77%), vagina (9%), and vulva (14%). Anal HR-HPV was detected in 92 patients (28%) and included HPV-16 in 24 (26%), HPV-18 in 6 (7%), and other HR-HPV types in 72 (78%) patients. Anal cytology was abnormal in 70 patients (23%) and included atypical squamous cells of undetermined significance (80%), low-grade squamous intraepithelial lesion (9%), high-grade intraepithelial lesion (HSIL; 1%), and atypical squamous cells-cannot rule out HSIL (10%). Of these patients, 55 (79%) underwent HRA. Anal biopsies were performed in 14 patients: 2 patients had anal intraepithelial neoplasia (AIN) 2/3, 1 patient had AIN 1, and 11 patients had negative biopsies. Both patients with AIN 2/3 had a history of cervical dysplasia. CONCLUSIONS: Our results suggest an elevated risk of anal HR-HPV infection and cytologic abnormalities in women with lower genital tract dysplasia/cancer. IMPACT: These results add to the growing body of evidence suggesting the need for evaluation of screening methods for anal dysplasia/cancer in this patient population to inform evidence-based screening recommendations.


Subject(s)
Anus Diseases , Anus Neoplasms , Carcinoma in Situ , Papillomavirus Infections , Squamous Intraepithelial Lesions , Uterine Cervical Neoplasms , Vulvar Neoplasms , Humans , Female , Cross-Sectional Studies , Papillomaviridae , Papillomavirus Infections/complications , Papillomavirus Infections/epidemiology , Papillomavirus Infections/diagnosis , Prevalence , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/epidemiology , Anus Neoplasms/diagnosis , Anus Diseases/epidemiology , Vulvar Neoplasms/epidemiology , Carcinoma in Situ/epidemiology , Vagina/pathology
SELECTION OF CITATIONS
SEARCH DETAIL